GlassScriptPhysician profile
Nassim Rad
NPI 1821385444
$231,188.31
in general payments reported to CMS, 2019-2025
9 companies · $74K in 2025
The $74K reported for 2025 was more than what 99% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,752 · 2020: $1,566 · 2021: $30K · 2022: $30K · 2023: $33K · 2024: $60K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Consulting Fee: $46K · Honoraria: $18K · Travel and Lodging: $10K · Food and Beverage: $2,197 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91,216.00 |
| Consulting Fee | $45,703.50 |
| Honoraria | $18,229.28 |
| Travel and Lodging | $10,103.99 |
| Food and Beverage | $2,197.41 |
| Education | $153.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $200,243.70 | 2019-2025 | Spinraza, Skyclarys, Spinraza |
| Itf Therapeutics LLC | $26,853.83 | 2025 | |
| Mitsubishi Tanabe Pharma Development America, INC. | $1,460.13 | 2020 | |
| Amylyx Pharmaceuticals, INC. | $1,389.22 | 2023 | Relyvrio |
| Genentech USA, INC. | $769.05 | 2024 | Evrysdi |
| Sarepta Therapeutics, INC. | $179.49 | 2023 | |
| Genentech, INC. | $172.36 | 2023 | Evrysdi |
| Catalyst Pharmaceuticals, INC. | $104.28 | 2025 | |
| Ucb, INC. | $16.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nassim Rad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.